1. Introduction of Maprotiline hydrochloride
Maprotiline hydrochloride is one kind of crystalline solid. Its chemical name is N-methyl-9,10-ethanoanthracene-9(10H)-propylamine hydrochloride. Besides, Maprotiline hydrochloride belongs to Active Pharmaceutical Ingredients;Chemical Amines;Amines;Intermediates & Fine Chemicals;Pharmaceuticals;Adrenoceptor. In addition, the Classification Code of it is Antidepressant; Drug / Therapeutic Agent; Human Data; Reproductive Effect. And its solubility in H₂O is 50 mg/mL.

2. Properties of Maprotiline hydrochloride
Physical properties about Maprotiline hydrochloride are:
(1)Flash Point: 187.7 °C; (2)Enthalpy of Vaporization: 65.04 kJ/mol; (3)Boiling Point: 399.6 °C at 760 mmHg; (4)Vapour Pressure: 1.35E-06 mmHg at 25°C; (5)Melting point: 230-232°C; (6)H-Bond Donor: 2; (7)H-Bond Acceptor: 1; (8)Rotatable Bond Count: 4; (9)Exact Mass: 313.159727; (10)MonoIsotopic Mass: 313.159727; (11)Topological Polar Surface Area: 12; (12)Heavy Atom Count: 22; (13)Formal Charge: 0; (14)Complexity: 339; (15)Isotope Atom Count: 0; (16)Defined Atom Stereocenter Count: 0; (17)Undefined Atom Stereocenter Count: 0; (18)Defined Bond Stereocenter Count: 0; (19)Undefined Bond Stereocenter Count: 0; (20)Covalently-Bonded Unit Count: 2.

3. Structure Descriptors of Maprotiline hydrochloride
(1)InChI: InChI=1S/C20H23N.ClH/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20;/h2-5,7-10,15,21H,6,11-14H2,1H3;1H
(2)InChIKey: NZDMFGKECODQRY-UHFFFAOYSA-N
(3)Canonical SMILES : CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24.Cl
(4)Smiles: c1cc2c(cc1)C1CCC2(CCCNC)c2ccccc12.Cl

4. Toxicity of Maprotiline hydrochloride

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cat	LDLo	intravenous	30mg/kg (30mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
cat	LDLo	oral	> 300mg/kg (300mg/kg)		Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
child	TDLo	oral	12mg/kg (12mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	American Journal of Emergency Medicine. Vol. 6, Pg. 247, 1988.
dog	LDLo	intravenous	20mg/kg (20mg/kg)		Bollettino Chimico Farmaceutico. Vol. 112, Pg. 782, 1973.
dog	LDLo	oral	20mg/kg (20mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
human	TDLo	oral	17mg/kg (17mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	British Medical Journal. Vol. 1, Pg. 1573, 1977.
man	TDLo	oral	490ug/kg (0.49mg/kg)	BEHAVIORAL: SLEEP	Journal of Clinical Psychiatry. Vol. 47, Pg. 210, 1986.
man	TDLo	oral	391mg/kg/1Y-I (391mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD KIDNEY, URETER, AND BLADDER: INCONTINENCE	Postgraduate Medical Journal. Vol. 55, Pg. 742, 1979.
mouse	LD50	intraperitoneal	125mg/kg (125mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 229, Pg. 163, 1977.
mouse	LD50	intravenous	31mg/kg (31mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
mouse	LD50	oral	480mg/kg (480mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 1, Pg. 207, 1975.
mouse	LD50	subcutaneous	310mg/kg (310mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 1, Pg. 207, 1975.
rabbit	LDLo	intravenous	20mg/kg (20mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
rabbit	LDLo	oral	> 1gm/kg (1000mg/kg)		Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
rat	LD50	intraperitoneal	72mg/kg (72mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
rat	LD50	intravenous	35mg/kg (35mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 1, Pg. 207, 1975.
rat	LD50	oral	760mg/kg (760mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
rat	LD50	subcutaneous	170mg/kg (170mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Bollettino Chimico Farmaceutico. Vol. 112, Pg. 601, 1973.
women	LDLo	oral	90mg/kg (90mg/kg)	BEHAVIORAL: COMA	Journal of Analytical Toxicology. Vol. 6, Pg. 199, 1982.
women	TDLo	oral	7mg/kg/1W-I (7mg/kg)	BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Journal of Clinical Pyschopharmacology. Vol. 3, Pg. 264, 1983.
women	TDLo	oral	20mg/kg (20mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	American Journal of Emergency Medicine. Vol. 2, Pg. 144, 1984.
women	TDLo	oral	63mg/kg/6W-I (63mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD KIDNEY, URETER, AND BLADDER: INCONTINENCE	Postgraduate Medical Journal. Vol. 55, Pg. 742, 1979.
women	TDLo	oral	75mg/kg (75mg/kg)	BEHAVIORAL: COMA CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	Intensive Care Medicine. Vol. 11, Pg. 220, 1985.

5. Safety information of Maprotiline hydrochloride
Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects: arrhythmias, coma, convulsions, distorted perceptions, general anesthesia, hallucinations, pulse rate increase, respiration changes. An experimental teratogen. Experimental reproductive effects. An antidepressant. When heated to decomposition it emits toxic fumes of NO_x and HCl.
Hazard CodesXn
Risk Statements 22
R22:Harmful if swallowed.
RIDADR 3249
WGK Germany 3
RTECS KJ4555000
HazardClass 6.1(b)
PackingGroup III

6. Uses of Maprotiline hydrochloride
Maprotiline hydrochlorid (CAS NO.10347-81-6) is antidepressant. It is a selective noradrenalin re-uptake inhibitor. It can be made into the maprotiline hydrochloride tablet. Maprotiline hydrochloride tablets are indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic depressive illness, depressed type (major depressive disorder). Maprotiline is also effective for the relief of anxiety associated with depression.